• Skip to main content
  • Skip to footer
Eco Friendly CBD OIL

Eco Friendly CBD OIL

The Best Eco Friendly CBD Oil

  • Home
  • CBD Health
  • Cannabis News
  • Contact

CBD OIL

Illinois Senate Approves Legislation Aimed at Improving Social Equity in Cannabis Licensing Process

January 14, 2021 by CBD OIL

Throughout the coronavirus pandemic, Michigan saw a significant increase in adult-use cannabis sales, according to a new report from Headset.

Michigan legalized adult-use cannabis in 2018 and had its first sale on Dec. 1, 2019. Although the state legalized recreational cannabis nearly two years ago, sales have yet to launch in the state’s most populous city, Detroit. 

Despite the pandemic and Detroit sales not yet launched, the data report from Headset, a company that provides leading insights into cannabis consumer trends, disclosed that adult-use cannabis sales in Michigan increased by 482% between January and December 2020, topping $500 million in sales.

Within eight months of the state’s first adult-use sale, Michigan’s medical and adult-use markets brought in $595 million combined, surpassing the Nevada market last year, which legalized recreational sales in January 2017.

The report revealed that traditional flower accounted for the majority of recreational sales at 47.8%, followed by vape pens at 20.6% and edibles at 14.9%.

Medical cannabis also saw a consistent increase in sales throughout the year. That market led cannabis sales in the state between January and June 2020; however, recreational sales took over the market in the second half of the year, exceeding medical by $5 million in July.

Looking forward, the report states that adult-use sales may continue to gross more sales than medical. Furthermore, the anticipation of adult-use cannabis hitting the Detroit market this year may further boost the predicted increase in sales of recreational cannabis.

Filed Under: Cannabis News

New Mexico Patient Caregiver and Provider File Motion to Enforce Plant Count Lawsuit

January 14, 2021 by CBD OIL

SANTA FE, N.M., Jan. 14, 2021 (GLOBE NEWSWIRE) — PRESS RELEASE — Nicole Sena, a medical cannabis caregiver to her young daughter with a rare form of epilepsy, and Ultra Health have reopened their lawsuit against the New Mexico Department of Health (NMDOH) to ensure an adequate supply of medicine.

The original lawsuit, filed in August 2016, contended the plant cap regulation promulgated by NMDOH was not in accordance with the Lynn and Erin Compassionate Use Act, the enabling legislation for New Mexico’s Medical Cannabis Program.

In November 2018, then-District Judge David K. Thomson ruled the department’s plant cap was arbitrary, capricious, and frustrated the purpose of the Lynn and Erin Compassionate Use Act. Sena and Ultra Health have reopened the case due to the department’s new regulation limiting adequate supply in the program.

NMDOH was court-ordered to raise the plant cap and find a data-driven solution to provide adequate supply for patients. In fall 2019, the new cap of 1,750 plants was promulgated. Even still, the new cap has failed to have a substantial effect on adequate supply in the program.

“While it may be true that DOH was delegated the authority to regulate the system of distribution of medical marijuana in this State, it may not create its own arbitrary production number that does not have a reasonable nexus in law or fact to adequate supply for patients in the program,” Judge Thomson stated in his 60-page ruling.

The ballooning of patient enrollment to 104,655 patients statewide and the effects of the COVID-19 pandemic have created an unprecedented demand for medical cannabis and therefore an extreme strain on available medicine in the program.

Per Judge Thomson’s order and the Lynn and Erin Compassionate Use Act, NMDOH has a duty to ensure every patient in the program has a three-month, uninterrupted adequate supply of medicine.

Furthermore, evidence obtained via an Inspection of Public Records Request (IPRA) found that the determination for the plant count was tied to slowing the growth of Ultra Health.

“It is odd that we are the only state with a plant count. Right now, I am trying to figure out the last possible date to hold a rule hearing (looks like July 5) in time to control the plant expansion of Ultra. They cannot produce a new crop for 16 weeks, so I have roughly four months to manage this,” then Secretary Kathy Kunkel stated in an email to Jane Wishner, a member of the governor’s senior staff, in February 2019.

“New Mexico’s medical cannabis program remains in a perpetual cycle of crisis—there is not an adequate supply of medical cannabis in state to benefit all patients, and the price of medicine puts it out of reach for too many medically fragile patients,” said Jacob Candelaria, counsel for Sena and Ultra Health, who is also a Senator from Albuquerque. “These problems are a direct result of the department’s failure to comply with the court’s trial order, and the law, which both require the department to ensure all medical cannabis patients can access the medicine they need at an affordable price.”

“What’s also very concerning here is the way the department and the governor’s office seemingly used their authority over the Medical Cannabis Program to target and retaliate against my client,” Candelaria continued. “It’s sad that our government is more interested in slowing the growth of my client’s ability to serve patients than in performing their legal obligations under the law or the court’s trial order.”

“While Judge Thomson’s ruling was a groundbreaking moment for medical cannabis patients’ rights in New Mexico, the work to actually provide an adequate supply of medicine is far from done,” said Duke Rodriguez, CEO and president of Ultra Health. “The department has a statutorily-mandated obligation to provide an adequate supply for patients. As the state’s largest provider, we similarly have an obligation to ensure our patients are receiving the standards of care that those benefiting from any other medication would receive. Simply put, the department must stop using their regulatory authority in a manner that thwarts patient access and instead promote adequate supply directly tied to the health and wellness of more than 104,000 New Mexican lives.”

Filed Under: Cannabis News

Aurora Announces Agreement with Great North Distributors Inc. for Canadian Retail Sales Execution

January 14, 2021 by CBD OIL

SANTA FE, N.M., Jan. 14, 2021 (GLOBE NEWSWIRE) — PRESS RELEASE — Nicole Sena, a medical cannabis caregiver to her young daughter with a rare form of epilepsy, and Ultra Health have reopened their lawsuit against the New Mexico Department of Health (NMDOH) to ensure an adequate supply of medicine.

The original lawsuit, filed in August 2016, contended the plant cap regulation promulgated by NMDOH was not in accordance with the Lynn and Erin Compassionate Use Act, the enabling legislation for New Mexico’s Medical Cannabis Program.

In November 2018, then-District Judge David K. Thomson ruled the department’s plant cap was arbitrary, capricious, and frustrated the purpose of the Lynn and Erin Compassionate Use Act. Sena and Ultra Health have reopened the case due to the department’s new regulation limiting adequate supply in the program.

NMDOH was court-ordered to raise the plant cap and find a data-driven solution to provide adequate supply for patients. In fall 2019, the new cap of 1,750 plants was promulgated. Even still, the new cap has failed to have a substantial effect on adequate supply in the program.

“While it may be true that DOH was delegated the authority to regulate the system of distribution of medical marijuana in this State, it may not create its own arbitrary production number that does not have a reasonable nexus in law or fact to adequate supply for patients in the program,” Judge Thomson stated in his 60-page ruling.

The ballooning of patient enrollment to 104,655 patients statewide and the effects of the COVID-19 pandemic have created an unprecedented demand for medical cannabis and therefore an extreme strain on available medicine in the program.

Per Judge Thomson’s order and the Lynn and Erin Compassionate Use Act, NMDOH has a duty to ensure every patient in the program has a three-month, uninterrupted adequate supply of medicine.

Furthermore, evidence obtained via an Inspection of Public Records Request (IPRA) found that the determination for the plant count was tied to slowing the growth of Ultra Health.

“It is odd that we are the only state with a plant count. Right now, I am trying to figure out the last possible date to hold a rule hearing (looks like July 5) in time to control the plant expansion of Ultra. They cannot produce a new crop for 16 weeks, so I have roughly four months to manage this,” then Secretary Kathy Kunkel stated in an email to Jane Wishner, a member of the governor’s senior staff, in February 2019.

“New Mexico’s medical cannabis program remains in a perpetual cycle of crisis—there is not an adequate supply of medical cannabis in state to benefit all patients, and the price of medicine puts it out of reach for too many medically fragile patients,” said Jacob Candelaria, counsel for Sena and Ultra Health, who is also a Senator from Albuquerque. “These problems are a direct result of the department’s failure to comply with the court’s trial order, and the law, which both require the department to ensure all medical cannabis patients can access the medicine they need at an affordable price.”

“What’s also very concerning here is the way the department and the governor’s office seemingly used their authority over the Medical Cannabis Program to target and retaliate against my client,” Candelaria continued. “It’s sad that our government is more interested in slowing the growth of my client’s ability to serve patients than in performing their legal obligations under the law or the court’s trial order.”

“While Judge Thomson’s ruling was a groundbreaking moment for medical cannabis patients’ rights in New Mexico, the work to actually provide an adequate supply of medicine is far from done,” said Duke Rodriguez, CEO and president of Ultra Health. “The department has a statutorily-mandated obligation to provide an adequate supply for patients. As the state’s largest provider, we similarly have an obligation to ensure our patients are receiving the standards of care that those benefiting from any other medication would receive. Simply put, the department must stop using their regulatory authority in a manner that thwarts patient access and instead promote adequate supply directly tied to the health and wellness of more than 104,000 New Mexican lives.”

Filed Under: Cannabis News

Cannabis Mogul Launches Pure Craft CBD

January 14, 2021 by CBD OIL

Media Contact:

Durée & Company, Inc.

954-723-9350 / purecraft@dureeandcompany.com

“Pure Till the Last Drop”

San Diego – Jan. 11, 2021 – When it comes to exceptional entrepreneurs, Jason Navarrete is at the top of the list. He built a massive cannabis conglomerate in Southern California worth more than $250 million — with 120,000 square feet across three industrial warehouses focusing on high-tech hydroponic indoor cultivation, manufacturing, distribution and retail. This masterful magnate sold that empire in early 2020 and transitioned from cultivating cannabis to creating the purest CBD products on the market with his newest venture called Pure Craft CBD.

What sets Pure Craft CBD apart from other CBD companies is its dedication to purity. Pure Craft products are 90% bio-available, where most CBD companies offer products that are no more than 18% bio-available. That’s why Pure Craft’s slogan is “Pure Till The Last Drop.” Being highly bio-available means Pure Craft products enter the body at a much quicker rate that’s more effective than other products because they are highly nanotized, broken down into particles that the body can absorb immediately.

Most CBD companies attempting to nanotize their product have gotten their products to 150 – 200 nanometers. Pure Craft CBD has broken that threshold to below 100 nanometers and, in some cases, as low as 5 nanometers.

Navarrete is also a stickler for transparency and consistency when it comes to what’s in Pure Craft products. All Pure Craft products come with third-party lab COAs (Certificates of Analysis) so consumers know exactly what’s in them and how they were tested consistently every time. Pure Craft CBD offers 16 different cannabis products and free two-day shipping.

Working closely with MIT researchers, Navarrete and his team have also developed nanotized water-soluble soft gels and nanotized CBD-infused vegan gummies, as well as a water-soluble nanotized CBD with nanotized melatonin to help with sleep. They’re also working on a full line of nano water-soluble tinctures from 600 – 3,000 mg with flavor profiles in peppermint, tropical, strawberry mojito, orange cream, blueberry and vanilla.”When it comes to CBD, a lot of companies online are looking at the money aspect of an emerging industry,” says Navarrete. “I’ve been cultivating cannabis for eighteen years. This industry is sorely lacking cultivation experts. That’s why scientists have reached out to work with me in their research.”

Navarrete explains a key factor in how he oversees his “seed to sale” process. “We only partner with farmers that understand the importance of genetics and science in regard to cultivating premium hemp biomass. Our products are made following the strictest guidelines and quality control measures, allowing us to call them pharmaceutical grade.”

Navarrete is also sharing that wisdom with young entrepreneurs as an adjunct professor at the Center for Entrepreneurship at California State University, Fullerton. He teaches young entrepreneurs about business basics from his streetwise experience and time-tested skills. “I’ve learned these lessons the hard way,” he explains. “Teaching these young students the insights, skills and tricks of the trade makes me feel as if I am contributing to their entrepreneurial dreams to help them become more successful faster. The way I look at it, everything is a game and how much money you make is how you keep score.”

About Pure Craft CBD

Pure Craft CBD believes in a “seed to sale” philosophy to offer high-quality products consistently made with full transparency. Its mission is to lead the industry in bringing high-quality hemp cannabidiol (CBD)-based products to the marketplace and educate the world on the benefits of hemp extract. Its product line includes nano-optimized broad spectrum water-soluble CBD tinctures along with soft gels, gummies, CBD with melatonin, CBD pet tincture and CBD broad spectrum oil.

Pure Craft: A Company Committed to Excellence

Tight quality controls and consistent manufacturing—All products are manufactured in a GMP compliant facility that is also FDA registered.

Pharmaceutical grade—All products are manufactured following the strictest guidelines and quality control measures, meeting the criteria of pharmaceutical grade.

Highest purity—All products contain no binders, fillers, excipients, dyes or unknown substances.

Consistency—All CBD comes from the same strain which ensures uniformity. Plus, CBD oil comes from the exact same extraction process in the same facility ensuring a product that’s reliable, predictable and effective.

Rigorous and thorough standards—Every CBD oil batch is tested in house and then by a third party for complete transparency to ensure products are of the highest quality available without any metals, pesticides or THC.

Proudly grown in the U.S.A. and organic—Many CBD companies grow their products overseas and manufacture and process them domestically. Pure Craft holds itself to rigorous farming standards and oversees every step of the production process to deliver high-quality products that are responsibly made.

Filed Under: CBD Health

Surna Announces Largest Contract in Its History

January 14, 2021 by CBD OIL

<![CDATA[

Boulder, Colorado, Jan. 14, 2021 (GLOBE NEWSWIRE) — PRESS RELEASE — Surna Inc. announced today that it recently signed a sales contract valued at $3.2 million.

The project in Arizona is for an approximately 53,000-square-foot facility. Surna is under contract to provide custom air handlers, heat recovery chillers and its StrataAir vertical racking air flow system for the cultivation, processing, drying and office spaces (the mechanical engineering design was done by Surna through a previous contract in October). Surna will also provide its SentryIQ environmental controls, and system start-up.

Tony McDonald, CEO, commented: “For the second time in six months, Surna is announcing its largest-ever single contract with this latest contract being nearly 15% larger than the previous record. Over the last several years Surna has invested heavily in technology R&D as well as in our engineering capabilities. The result has been an expanding portfolio of product and system offerings and enhanced engineering sophistication. With Surna’s expanded array of technology offerings, our engineering and sales teams were able to present several options to the client, giving them the opportunity to compare and contrast design approaches and choose the solution best tailored to their particular goals, budget and cultivation methods.”

]]>

Filed Under: Cannabis News

Indiana Lawmaker Introduces Cannabis Legalization Bills

January 14, 2021 by CBD OIL

<![CDATA[

Indiana Sen. Karen Tallian has introduced two pieces of legislation that would legalize and regulate medical and adult-use cannabis, as well as hemp, according to a local WLWT report.

S.B. 87 would create a Cannabis Compliance Commission to regulate cannabis and hemp in the state, while S.B. 223 would decriminalize the possession of up to two ounces of cannabis, WLWT reported. Currently, Indiana law allows cannabis possession charges for any amount of cannabis, according to the news outlet.

Tallian told WDRB that she has been working for a decade to reform Indiana’s cannabis laws, and that with more states adopting legalization, it is time for Indiana to embrace reform.

]]>

Filed Under: Cannabis News

Virginia Governor Proposes Adult-Use Cannabis Legalization Bill

January 14, 2021 by CBD OIL

<![CDATA[

Virginia Gov. Ralph Northam proposed an adult-use cannabis legalization bill Jan. 13, according to The Virginian-Pilot.

The legislation, which is co-sponsored by Sens. Louise Lucas (D-Portsmouth) and Adam Ebbin (D-Alexandria), would allow sales to launch Jan. 1, 2023, and calls for the licensing of cultivators, processors, distributors/wholesalers, retailers and testing labs, the news outlet reported.

The bill imposes a possession limit of one ounce, and levies a 21% tax on adult-use cannabis sales, according to The Virginian-Pilot. Municipalities would be allowed to impose an additional 3% tax on dispensaries, the news outlet reported.

A portion of the tax revenue generated from an adult-use cannabis market will be directed to pre-kindergarten access for at-risk children, according to The Virginian-Pilot, as well as substance abuse prevention efforts in schools.

The legislation also includes provisions to automatically expunge past cannabis-related misdemeanor offenses, the news outlet reported, as well as a system for petition-based expungements for felonies.

The Virginia Alcoholic Beverage Control Authority will regulate and oversee the adult-use cannabis industry under the bill, and will include a governor-appointed, seven-member Cannabis Control Advisory Board, according to The Virginian-Pilot.

Northam’s proposal also outlines “diverse participation” plans, which include a licensing process meant to support those identified as social equity applicants, as well as low- or no-interest loans and waived or reduced application and licensing fees for qualified applicants, the news outlet reported.

The legislation also includes a home grow provision that would allow Virginians to cultivate up to two mature and two immature plants per household, according to The Virginian-Pilot.

Northam initially announced plans to introduce a cannabis legalization bill in November, and a separate bill to legalize adult-use cannabis has been introduced this year by Del. Steve Heretick (D-Portsmouth).

]]>

Filed Under: Cannabis News

Cresco Labs to Expand Into Florida Through Acquisition of Bluma Wellness Inc.

January 14, 2021 by CBD OIL

As the COVID-19 pandemic rages on, cannabis businesses—many of which were deemed “essential” during coronavirus-related shutdowns—have become accustomed to implementing policies and procedures to keep their employees and customers safe, from mask-wearing and sanitation protocols to how they handle COVID testing at their facilities. Now, as the first vaccines are released across the country, primarily to frontline and health care workers to start, Bianchi & Brandt partner Laura Bianchi says cannabis businesses should develop internal policies regarding vaccination.

“It really is an evolving topic, as it has been all year long,” Bianchi tells Cannabis Business Times and Cannabis Dispensary. “It changes week to week, but I do think that cannabis companies are prepared [to handle the vaccine] because they had to deal with [the pandemic] in such a front-facing manner throughout the entirety of 2020. I think for a lot of businesses, they could say, ‘Everybody work remotely,’ and they haven’t had to come up with the thoughtful policies and procedures to keep everybody safe. Cannabis companies for the most part have, so I think that puts them ahead of the curve in going, ‘OK, now let’s figure out this next phase. How do we adopt and implement things that will make sense for our patients and our staff?’”

Businesses should be prepared to move quickly once the COVID-19 vaccine is available to the general public, Bianchi says, and when developing their policies regarding vaccination, business owners should consider that in many markets, cannabis companies operate medically. Dispensaries must be prepared to deal with ill patients who may be in higher-risk populations, and Bianchi says many of her cannabis clients are considering requiring their employees to be vaccinated for this reason.

“We always advise [that] there has to be exceptions for people who have some sort of medical issue or seriously held medical beliefs,” she says. “But this is a health care facility, so we can’t place other people and patients at risk. If we can require people to take the vaccination, it’s a benefit not only to the business owners and to all of their employees, but [also] to the patients who come in.”

Many states are “at will” employment states, Bianchi says, which means that employers have the right to establish company and workplace policies, requirements and conditions—such as those relating to mandatory vaccination—as long as they don’t violate any constitutionally protected class or right.

In addition, this past December, the Equal Employment Opportunity Commission (EEOC) determined that an employer’s act of requiring employee vaccinations alone would not violate the Americans with Disabilities Act (ADA), Bianchi says, which could further strengthen an employer’s position on required vaccinations.

Although it appears, then, that employers can legally require employees to receive the COVID-19 vaccine, Bianchi says the issue is likely going to be the subject of debate and litigation going forward.

“Employers really do need to weigh the risks and benefits of requiring vaccinations to ensure the health, safety and welfare of their employees, clients and business as a whole, versus any potential liability related to implementing such a requirement,” she says.

Many of Bianchi’s clients have asked how to approach mandatory vaccination from an operational standpoint, and she has advised them to be as detailed as possible in their policies and procedures. First and foremost, she says employers should issue a uniform vaccination policy in writing, and this policy must be carefully constructed.

For example, in many facilities, such as dispensaries and cultivation and manufacturing operations, employees cannot work remotely to slow the spread of the coronavirus, and they work in close proximity to one another. In these situations, Bianchi says it might make sense for employers to require mandatory vaccination.

“A lot of our clients also have corporate offices, and for corporate offices, there’s a little bit more flexibility in saying, ‘If we don’t want to implement a must-have vaccination policy, can some of these individuals work remotely?’” she says. “Even that can be a slippery slope because you want to make these rules and requirements cohesive across the board, but there is some flexibility where maybe you’re in a location where you don’t always have to be on-site to do work.”

In most cases, Bianchi advises companies to evenly apply vaccination policies across the board, and business owners should meet with their attorneys to go over exceptions to mandatory vaccine policies, including requirements for employees looking to prove that they are in a situation where they would be exempt from such a policy.

If an employee refuses to follow a mandatory vaccination policy for reasons outside of the allocated exemptions, Bianchi says an employer could legally take disciplinary action, including termination.

“Again, most states are ‘at will’ employment states, so if an employer implements a COVID-19 employee vaccination policy … and an employee simply refuses, that employee may be subject to discipline, up to and including termination,” she says. “This is also something employers may opt to contractually require through an employment agreement. In that case, an employee’s refusal would be deemed a breach of contract and in the same manner, be subject to discipline, up to and including termination.”

Employers should also consider whether they will pay for mandatory vaccines if they are not covered by health insurance, as well as the timeframe for employees to be vaccinated.

“A lot of our employers are saying, ‘We’ll do this as a group—either we’ll take our employees to a certain location, or we’ll have them come to us,’” Bianchi says. “[Many businesses] did this with COVID testing, as well, [to make] it easier for employees, so they’re not searching for a location, they’re not paying fees—the employers are taking that on when they can.”

Creating a vaccination policy for seasonal workers at cultivation facilities could also pose a challenge, she adds, and employers must decide whether to require these types of hires to receive the vaccine, as well.

“You’ve really got to think about how do we keep everybody safe?” Bianchi says. “They’re going to go home to their families, [and] we’ve seen how quickly [the virus] can spread. This is an industry where it can and certainly does spread fast, so we’re trying to think of those things ahead of time, and every business has to figure out how to function financially but also help employees who may be in vulnerable financial situations get through this.”

Filed Under: Cannabis News

Canopy Growth Announces Filing of Early Warning Report Regarding TerrAscend Corp.

January 14, 2021 by CBD OIL

As the COVID-19 pandemic rages on, cannabis businesses—many of which were deemed “essential” during coronavirus-related shutdowns—have become accustomed to implementing policies and procedures to keep their employees and customers safe, from mask-wearing and sanitation protocols to how they handle COVID testing at their facilities. Now, as the first vaccines are released across the country, primarily to frontline and health care workers to start, Bianchi & Brandt partner Laura Bianchi says cannabis businesses should develop internal policies regarding vaccination.

“It really is an evolving topic, as it has been all year long,” Bianchi tells Cannabis Business Times and Cannabis Dispensary. “It changes week to week, but I do think that cannabis companies are prepared [to handle the vaccine] because they had to deal with [the pandemic] in such a front-facing manner throughout the entirety of 2020. I think for a lot of businesses, they could say, ‘Everybody work remotely,’ and they haven’t had to come up with the thoughtful policies and procedures to keep everybody safe. Cannabis companies for the most part have, so I think that puts them ahead of the curve in going, ‘OK, now let’s figure out this next phase. How do we adopt and implement things that will make sense for our patients and our staff?’”

Businesses should be prepared to move quickly once the COVID-19 vaccine is available to the general public, Bianchi says, and when developing their policies regarding vaccination, business owners should consider that in many markets, cannabis companies operate medically. Dispensaries must be prepared to deal with ill patients who may be in higher-risk populations, and Bianchi says many of her cannabis clients are considering requiring their employees to be vaccinated for this reason.

“We always advise [that] there has to be exceptions for people who have some sort of medical issue or seriously held medical beliefs,” she says. “But this is a health care facility, so we can’t place other people and patients at risk. If we can require people to take the vaccination, it’s a benefit not only to the business owners and to all of their employees, but [also] to the patients who come in.”

Many states are “at will” employment states, Bianchi says, which means that employers have the right to establish company and workplace policies, requirements and conditions—such as those relating to mandatory vaccination—as long as they don’t violate any constitutionally protected class or right.

In addition, this past December, the Equal Employment Opportunity Commission (EEOC) determined that an employer’s act of requiring employee vaccinations alone would not violate the Americans with Disabilities Act (ADA), Bianchi says, which could further strengthen an employer’s position on required vaccinations.

Although it appears, then, that employers can legally require employees to receive the COVID-19 vaccine, Bianchi says the issue is likely going to be the subject of debate and litigation going forward.

“Employers really do need to weigh the risks and benefits of requiring vaccinations to ensure the health, safety and welfare of their employees, clients and business as a whole, versus any potential liability related to implementing such a requirement,” she says.

Many of Bianchi’s clients have asked how to approach mandatory vaccination from an operational standpoint, and she has advised them to be as detailed as possible in their policies and procedures. First and foremost, she says employers should issue a uniform vaccination policy in writing, and this policy must be carefully constructed.

For example, in many facilities, such as dispensaries and cultivation and manufacturing operations, employees cannot work remotely to slow the spread of the coronavirus, and they work in close proximity to one another. In these situations, Bianchi says it might make sense for employers to require mandatory vaccination.

“A lot of our clients also have corporate offices, and for corporate offices, there’s a little bit more flexibility in saying, ‘If we don’t want to implement a must-have vaccination policy, can some of these individuals work remotely?’” she says. “Even that can be a slippery slope because you want to make these rules and requirements cohesive across the board, but there is some flexibility where maybe you’re in a location where you don’t always have to be on-site to do work.”

In most cases, Bianchi advises companies to evenly apply vaccination policies across the board, and business owners should meet with their attorneys to go over exceptions to mandatory vaccine policies, including requirements for employees looking to prove that they are in a situation where they would be exempt from such a policy.

If an employee refuses to follow a mandatory vaccination policy for reasons outside of the allocated exemptions, Bianchi says an employer could legally take disciplinary action, including termination.

“Again, most states are ‘at will’ employment states, so if an employer implements a COVID-19 employee vaccination policy … and an employee simply refuses, that employee may be subject to discipline, up to and including termination,” she says. “This is also something employers may opt to contractually require through an employment agreement. In that case, an employee’s refusal would be deemed a breach of contract and in the same manner, be subject to discipline, up to and including termination.”

Employers should also consider whether they will pay for mandatory vaccines if they are not covered by health insurance, as well as the timeframe for employees to be vaccinated.

“A lot of our employers are saying, ‘We’ll do this as a group—either we’ll take our employees to a certain location, or we’ll have them come to us,’” Bianchi says. “[Many businesses] did this with COVID testing, as well, [to make] it easier for employees, so they’re not searching for a location, they’re not paying fees—the employers are taking that on when they can.”

Creating a vaccination policy for seasonal workers at cultivation facilities could also pose a challenge, she adds, and employers must decide whether to require these types of hires to receive the vaccine, as well.

“You’ve really got to think about how do we keep everybody safe?” Bianchi says. “They’re going to go home to their families, [and] we’ve seen how quickly [the virus] can spread. This is an industry where it can and certainly does spread fast, so we’re trying to think of those things ahead of time, and every business has to figure out how to function financially but also help employees who may be in vulnerable financial situations get through this.”

Filed Under: Cannabis News

Rubicon Organics Receives Sales Amendment from Health Canada

January 14, 2021 by CBD OIL

As the COVID-19 pandemic rages on, cannabis businesses—many of which were deemed “essential” during coronavirus-related shutdowns—have become accustomed to implementing policies and procedures to keep their employees and customers safe, from mask-wearing and sanitation protocols to how they handle COVID testing at their facilities. Now, as the first vaccines are released across the country, primarily to frontline and health care workers to start, Bianchi & Brandt partner Laura Bianchi says cannabis businesses should develop internal policies regarding vaccination.

“It really is an evolving topic, as it has been all year long,” Bianchi tells Cannabis Business Times and Cannabis Dispensary. “It changes week to week, but I do think that cannabis companies are prepared [to handle the vaccine] because they had to deal with [the pandemic] in such a front-facing manner throughout the entirety of 2020. I think for a lot of businesses, they could say, ‘Everybody work remotely,’ and they haven’t had to come up with the thoughtful policies and procedures to keep everybody safe. Cannabis companies for the most part have, so I think that puts them ahead of the curve in going, ‘OK, now let’s figure out this next phase. How do we adopt and implement things that will make sense for our patients and our staff?’”

Businesses should be prepared to move quickly once the COVID-19 vaccine is available to the general public, Bianchi says, and when developing their policies regarding vaccination, business owners should consider that in many markets, cannabis companies operate medically. Dispensaries must be prepared to deal with ill patients who may be in higher-risk populations, and Bianchi says many of her cannabis clients are considering requiring their employees to be vaccinated for this reason.

“We always advise [that] there has to be exceptions for people who have some sort of medical issue or seriously held medical beliefs,” she says. “But this is a health care facility, so we can’t place other people and patients at risk. If we can require people to take the vaccination, it’s a benefit not only to the business owners and to all of their employees, but [also] to the patients who come in.”

Many states are “at will” employment states, Bianchi says, which means that employers have the right to establish company and workplace policies, requirements and conditions—such as those relating to mandatory vaccination—as long as they don’t violate any constitutionally protected class or right.

In addition, this past December, the Equal Employment Opportunity Commission (EEOC) determined that an employer’s act of requiring employee vaccinations alone would not violate the Americans with Disabilities Act (ADA), Bianchi says, which could further strengthen an employer’s position on required vaccinations.

Although it appears, then, that employers can legally require employees to receive the COVID-19 vaccine, Bianchi says the issue is likely going to be the subject of debate and litigation going forward.

“Employers really do need to weigh the risks and benefits of requiring vaccinations to ensure the health, safety and welfare of their employees, clients and business as a whole, versus any potential liability related to implementing such a requirement,” she says.

Many of Bianchi’s clients have asked how to approach mandatory vaccination from an operational standpoint, and she has advised them to be as detailed as possible in their policies and procedures. First and foremost, she says employers should issue a uniform vaccination policy in writing, and this policy must be carefully constructed.

For example, in many facilities, such as dispensaries and cultivation and manufacturing operations, employees cannot work remotely to slow the spread of the coronavirus, and they work in close proximity to one another. In these situations, Bianchi says it might make sense for employers to require mandatory vaccination.

“A lot of our clients also have corporate offices, and for corporate offices, there’s a little bit more flexibility in saying, ‘If we don’t want to implement a must-have vaccination policy, can some of these individuals work remotely?’” she says. “Even that can be a slippery slope because you want to make these rules and requirements cohesive across the board, but there is some flexibility where maybe you’re in a location where you don’t always have to be on-site to do work.”

In most cases, Bianchi advises companies to evenly apply vaccination policies across the board, and business owners should meet with their attorneys to go over exceptions to mandatory vaccine policies, including requirements for employees looking to prove that they are in a situation where they would be exempt from such a policy.

If an employee refuses to follow a mandatory vaccination policy for reasons outside of the allocated exemptions, Bianchi says an employer could legally take disciplinary action, including termination.

“Again, most states are ‘at will’ employment states, so if an employer implements a COVID-19 employee vaccination policy … and an employee simply refuses, that employee may be subject to discipline, up to and including termination,” she says. “This is also something employers may opt to contractually require through an employment agreement. In that case, an employee’s refusal would be deemed a breach of contract and in the same manner, be subject to discipline, up to and including termination.”

Employers should also consider whether they will pay for mandatory vaccines if they are not covered by health insurance, as well as the timeframe for employees to be vaccinated.

“A lot of our employers are saying, ‘We’ll do this as a group—either we’ll take our employees to a certain location, or we’ll have them come to us,’” Bianchi says. “[Many businesses] did this with COVID testing, as well, [to make] it easier for employees, so they’re not searching for a location, they’re not paying fees—the employers are taking that on when they can.”

Creating a vaccination policy for seasonal workers at cultivation facilities could also pose a challenge, she adds, and employers must decide whether to require these types of hires to receive the vaccine, as well.

“You’ve really got to think about how do we keep everybody safe?” Bianchi says. “They’re going to go home to their families, [and] we’ve seen how quickly [the virus] can spread. This is an industry where it can and certainly does spread fast, so we’re trying to think of those things ahead of time, and every business has to figure out how to function financially but also help employees who may be in vulnerable financial situations get through this.”

Filed Under: Cannabis News

  • « Go to Previous Page
  • Go to page 1
  • Interim pages omitted …
  • Go to page 86
  • Go to page 87
  • Go to page 88
  • Go to page 89
  • Go to page 90
  • Interim pages omitted …
  • Go to page 116
  • Go to Next Page »

Footer

  • Home
  • Privacy Policy
  • Terms of Service